This lecture introduces and describes H63D Syndrome Type-1, a distinct and serious clinical condition linked to a homozygous H63D mutation of the HFE gene. Unlike typical hemochromatosis, which involves high ferritin, this syndrome is characterized by low transferrin and high transferrin saturation, leading to the formation of toxic non-transferrin-bound iron (NTBI). NTBI accumulation, particularly in brain structures like the substantia nigra, triggers oxidative inflammation and causes a range of neurological symptoms, including movement disorders, cognitive impairment, and sleep disturbances, alongside issues in other organ systems. Diagnosis relies on specific lab findings and genetic testing for the homozygous mutation, but no causal treatment exists currently, with management focusing on dietary iron control and symptomatic relief.